What is xCures?
Founded in 2018 and based in Oakland, California, xCures is at the forefront of developing an AI-driven platform designed to conduct 'Virtual Trials'. This innovative methodology continuously learns from the clinical experiences of all patients across all treatments, in real-time. The company's 'Virtual Tumor Board' adaptively plans individual patient treatment regimens to optimize outcomes, while simultaneously coordinating these plans across the entire patient population to maximize collective learning and accelerate therapeutic advancements.
How much funding has xCures raised?
xCures has raised a total of $58.7M across 2 funding rounds:
Series A
$12.7M
Series B
$46M
Series A (2021): $12.7M with participation from Vanedge Capital and Boehringer Ingelheim Venture Fund
Series B (2026): $46M led by Innovius Capital and Spring Mountain Capital
Key Investors in xCures
Vanedge Capital
Vanedge Capital is an early-stage venture capital fund based in Vancouver, Canada, focusing on empowering visionary technologists in the Hard Tech and AI & Analytics sectors. The firm leverages its deep domain expertise, operating experience, and extensive network to support exceptional entrepreneurs in scaling their businesses.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science aimed at redefining care standards and developing new medicines for patients. The fund focuses on first-in-class, disease-modifying therapeutics across various modalities.
Innovius Capital
Innovius Venture Capital is a venture capital firm focused on supporting SaaS and AI founders, particularly those in Series A and B stages. The firm differentiates itself by embedding proven go-to-market specialists and seasoned operators into the teams of ambitious founders, providing hands-on support to accelerate growth.
What's next for xCures?
The substantial enterprise-level funding, including a recent major strategic investment, positions xCures for accelerated growth and market penetration. This capital infusion is expected to fuel further development of its AI-based virtual trial technology, expand its operational capacity, and potentially forge new strategic partnerships within the pharmaceutical and healthcare sectors. The company's trajectory suggests a focus on scaling its platform to become an indispensable tool for optimizing cancer treatment and drug development.
See full xCures company page
